Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05853783

Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™

The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The study objectives are to:

  • Evaluate STRATICYTE™ sensitivity and specificity in a cohort of patients that meet the inclusion/exclusion criteria.
  • Identify patient and clinical characteristics influencing the sensitivity and specificity of the STRATICYTE™ model.
  • Estimate the correlation between STRATICYTE™ outcome and time to a positive diagnosis of oral cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • From the archive, any patient who presents with clinically evident oral lesions and biopsy-proven dysplasia (punch or scalpel biopsies; any grade or classification system)
  • Patients with initial oral lesions with epithelial atypia suspicious for neoplasia, with:
  • No histological evidence of cancer with clinical follow-up data for a period of at least five years; or
  • OSCC development (histologic or documented evidence of invasive cancer).
  • Patients who had archived biopsy tissue blocks of a previous oral lesion(s) meeting the above criteria and retained at the same clinical center.

Exclusion criteria

  • Patients with oral lesions or dysplasia with no indication of OSCC development or follow-up data of less than five years in non-OSCC patients.
  • Patients diagnosed with oral epithelial dysplasia concomitant with OSCC at the time of the biopsy's original pathology report or a subsequent clinical note of cancer progression within three months post-biopsy.

Treatment and study plan

STRATICYTE™ Test

Other

Assessment for risk of progression to oral cancer

Other names: S100A7 Immunohistochemistry Signature-based Test

Primary outcomes

  1. Sensitivity and Specificity

    Time frame: 5 years

    Standard measures of accuracy calculated using cross-tabulation of predicted risk category and confirmed cancer progression over a 5-year period from biopsy

  2. Survival analysis

    Time frame: 5 years

    Kaplan-Meier analyses to compare time to a positive diagnosis of oral cancer between patients/biopsies with a STRATICYTE™ classification of Low- and Elevated-Risk.

Secondary outcomes

  1. AUC

    Time frame: 5 years

    Area under the receiver operator curve

  2. C-index (Harrell's)

    Time frame: 5 years

    From all possible pairs of patients, compute the number of concordant and discordant pairs. Compute C-index as the proportion of all possible pairs that are concordant.

Study contacts

Contact information is provided by the study sponsor or research team.

Jason TK Hwang, HBSc, MSc, PhD

CONTACT

[email protected]

1-647-255-1370

Jody Filkowski, BSc, MSc, PhD

CONTACT

[email protected]

1-825-305-0749

Sponsors and collaborators

Lead sponsor

Proteocyte Diagnostics Inc.

Industry

Collaborators

  • Loma Linda University
  • Minnesota Oral & Facial Surgery
  • The University of Texas Health Science Center, Houston
  • University of Alabama at Birmingham

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
May 11, 2023
Registry last updated
Nov 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.